Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 13/20 | 0.36 |
| ▸ | THRA | P10827 | 3/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6455277 | 0.90 | THRB (0.38) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL6459710 | 0.79 | THRB (0.40) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL5760209 | 0.76 | P2RX7 (0.40) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL6465988 | 0.75 | HPGD (0.43) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL6454313 | 0.75 | THRB (0.40) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL6459165 | 0.74 | MEN1 (0.40) | MEN1NR1I2KMT2ATHRBTHRA | |
| Hydrochloric Acid SCHEMBL6461599 | 0.71 | THRB (0.39) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL7705484 | 0.69 | THRB (0.46) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL7705420 | 0.68 | MEN1 (0.39) | MEN1NR1I2KMT2ATHRBTHRA | |
| SCHEMBL6455399 | 0.66 | MEN1 (0.49) | MEN1NR1I2KMT2ATHRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | JANSSEN CILAG S.A. (FR) | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010177-A1 | IL-5 inhibiting 6-azauracil derivatives | ALOX5, IL5, IL6ST | MEN1 4651/4885NR1I2 416/4885KMT2A 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.